Pharmacy Medical Necessity Guidelines: Zelapar® (selegiline)

Effective: March 10, 2026

Prior Authorization Required	√	Type of Review – Care Management	
Not Covered		Type of Review – Clinical Review	√
Pharmacy (RX) or Medical (MED) Benefit	RX	Department to Review	RXUM
These pharmacy medical necessity guidelines apply to the following: ☒ Tufts Health RITogether – A Rhode Island Medicaid Plan		**Fax Numbers:** RXUM: 617.673.0939	

Note: This guideline does not apply to Medicare Members (includes dual eligible Members).

OVERVIEW

FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS

Zelapar (selegiline), a monoamine oxidase type B (MAO-B) inhibitor, is an orally disintegrating tablet indicated as an adjunct in the management of patients with Parkinson's disease being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy.

COVERAGE GUIDELINES

The plan may authorize coverage of **Zelapar (selegiline)** for Members when **ALL** of the following criteria are met:

1. The Member is diagnosed with Parkinson's disease

AND

2. The Member is using selegiline concomitantly with levodopa/carbidopa

AND

3. One of the following:
   a) The Member is new to the health plan and is already stabilized on the medication

   OR

   b) There is difficulty with the administration of, an intolerance to, or a risk of non-compliance with one of the preferred monoamine oxidase inhibitor agents: selegiline tablet or capsule, or rasagiline tablet

LIMITATIONS

None

CODES

None

REFERENCES

1. Zelapar (selegiline) [prescribing information.] Bridgewater, NJ: Bausch Health US, LLC; June 2021.

APPROVAL HISTORY

October 11, 2022: Reviewed by Pharmacy & Therapeutics Committee.

Subsequent endorsement date(s) and changes made:

1. June 13, 2023: No changes.
2. March 12, 2024: Effective April 1, 2024, updated RxUM fax number.
3. March 11, 2025: No changes
4. March 10, 2026: No changes.

BACKGROUND, PRODUCT AND DISCLAIMER INFORMATION

Pharmacy Medical Necessity Guidelines have been developed for determining coverage for plan benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. The plan makes coverage decisions on a case-by-case basis considering the individual member's health care needs. Pharmacy Medical Necessity Guidelines are developed for selected therapeutic classes or drugs found to be safe, but proven to be effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. The plan revises and updates Pharmacy Medical

Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Pharmacy Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern.

Treating providers are solely responsible for the medical advice and treatment of members. The use of this policy is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization and utilization management guidelines when applicable, and adherence to plan policies and procedures and claims editing logic.

Provider Services